SwePub
Tyck till om SwePub Sök här!
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:uu-296850"
 

Sökning: onr:"swepub:oai:DiVA.org:uu-296850" > Assessment of bone ...

Assessment of bone marrow lymphocytic status during tyrosine kinase inhibitor therapy and its relation to therapy response in chronic myeloid leukaemia

El Missiry, Mohamed (författare)
Univ Helsinki, Dept Hematol, Hematol Res Unit Helsinki, Haartmaninkatu 8,POB 700, FIN-00290 Helsinki, Finland.;Univ Helsinki, Cent Hosp, Ctr Comprehens Canc, Haartmaninkatu 8,POB 700, FIN-00290 Helsinki, Finland.
Awad, Shady Adnan (författare)
Univ Helsinki, Dept Hematol, Hematol Res Unit Helsinki, Haartmaninkatu 8,POB 700, FIN-00290 Helsinki, Finland.;Univ Helsinki, Cent Hosp, Ctr Comprehens Canc, Haartmaninkatu 8,POB 700, FIN-00290 Helsinki, Finland.
Rajala, Hanna L. (författare)
Univ Helsinki, Dept Hematol, Hematol Res Unit Helsinki, Haartmaninkatu 8,POB 700, FIN-00290 Helsinki, Finland.;Univ Helsinki, Cent Hosp, Ctr Comprehens Canc, Haartmaninkatu 8,POB 700, FIN-00290 Helsinki, Finland.
visa fler...
Al-Samadi, Ahmed (författare)
Univ Helsinki, Inst Clin Med, Helsinki, Finland.
Ekblom, Marja (författare)
Skane Univ Hosp, Lund, Sweden.
Markevan, Berit (författare)
Umea Univ Hosp, Dept Hematol, S-90185 Umea, Sweden.
Astrand-Grundstrom, Ingbritt (författare)
Skane Univ Hosp, Lund, Sweden.
Wold, Maren (författare)
Norwegian Univ Sci & Technol NTNU, St Olavs Hosp, Dept Hematol, Trondheim, Norway.
Svedahl, Ellen Rabben (författare)
Norwegian Univ Sci & Technol NTNU, St Olavs Hosp, Dept Hematol, Trondheim, Norway.
Juhl, Birgitte Ravn (författare)
Univ Copenhagen, Rigshosp, Dept Pathol, DK-2100 Copenhagen, Denmark.
Bjerrum, Ole Weis (författare)
Univ Copenhagen Hosp, Rigshosp, Dept Hematol, DK-2100 Copenhagen, Denmark.
Haulin, Inger (författare)
Uppsala universitet,Institutionen för immunologi, genetik och patologi
Porkka, Kimmo (författare)
Univ Helsinki, Dept Hematol, Hematol Res Unit Helsinki, Haartmaninkatu 8,POB 700, FIN-00290 Helsinki, Finland.;Univ Helsinki, Cent Hosp, Ctr Comprehens Canc, Haartmaninkatu 8,POB 700, FIN-00290 Helsinki, Finland.
Olsson-Strömberg, Ulla (författare)
Uppsala universitet,Hematologi,Univ Helsinki, Dept Clin Chem, SF-00100 Helsinki, Finland.
Hjorth-Hansen, Henrik (författare)
Norwegian Univ Sci & Technol NTNU, St Olavs Hosp, Dept Hematol, Trondheim, Norway.
Mustjoki, Satu (författare)
Univ Helsinki, Dept Hematol, Hematol Res Unit Helsinki, Haartmaninkatu 8,POB 700, FIN-00290 Helsinki, Finland.;Univ Helsinki, Cent Hosp, Ctr Comprehens Canc, Haartmaninkatu 8,POB 700, FIN-00290 Helsinki, Finland.;Univ Helsinki, Dept Clin Chem, SF-00100 Helsinki, Finland.
visa färre...
Univ Helsinki, Dept Hematol, Hematol Res Unit Helsinki, Haartmaninkatu 8,POB 700, FIN-00290 Helsinki, Finland;Univ Helsinki, Cent Hosp, Ctr Comprehens Canc, Haartmaninkatu 8,POB 700, FIN-00290 Helsinki, Finland. Univ Helsinki, Inst Clin Med, Helsinki, Finland. (creator_code:org_t)
2016-01-08
2016
Engelska.
Ingår i: Journal of Cancer Research and Clinical Oncology. - : Springer Science and Business Media LLC. - 0171-5216 .- 1432-1335. ; 142:5, s. 1041-1050
Relaterad länk:
https://helda.helsin...
visa fler...
https://urn.kb.se/re...
https://doi.org/10.1...
visa färre...
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Tyrosine kinase inhibitors (TKIs) used in the treatment of chronic myeloid leukaemia have been reported to induce immunomodulatory effects. We aimed to assess peripheral blood (PB) and bone marrow (BM) lymphocyte status at the diagnosis and during different TKI therapies and correlate it with treatment responses. BM and PB samples were acquired from 105 first-line TKI-treated patients. Relative number of BM lymphocytes was evaluated from MGG-stained BM aspirates, and immunophenotypic analyses were performed with multicolour flow cytometry. Early 3-month expansion of BM lymphocytes was found during all different TKIs (imatinib n = 71, 20 %; dasatinib n = 25, 21 %; nilotinib n = 9, 22 %; healthy controls n = 14, 12 %, p < 0.0001). Increased PB lymphocyte count was only observed during dasatinib therapy. The BM lymphocyte expansion was associated with early molecular response; patients with 3-month BCR-ABL1 < 10 % showed higher lymphocyte counts than patients with BCR-ABL1 > 10 % (23 vs. 17 %, p < 0.05). Detailed phenotypic analysis showed that BM lymphocyte expansion consisted of various lymphocyte subclasses, but especially the proportion of CD19+ B cells and CD3negCD16/56+ NK cells increased from diagnostic values. During dasatinib treatment, the lymphocyte balance in both BM and PB was shifted more to cytotoxic direction (increased CD8+CD57+ and CD8+HLA-DR+ cells, and low T regulatory cells), whereas no major immunophenotypic differences were observed between imatinib and nilotinib patients. Early BM lymphocytosis occurs with all current first-line TKIs and is associated with better treatment responses. PB and BM immunoprofile during dasatinib treatment markedly differs from both imatinib- and nilotinib-treated patients.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)

Nyckelord

Bone marrow
Lymphocyte
CML
Tyrosine kinase inhibitor
Therapy response

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy